This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
* Benchmark UCB's performance against key rivals in the prescription pharmaceutical sector
* Determine the extent to which UCB's next-generation of CNS medications will protect revenues from the decline of its Keppra franchise
* Examine the long-term sales potential offered by Cimzia after its long-awaited approvals for Crohn's disease and rheumatoid arthritis
For more information or to purchase this report, go to:
- http://www.fastmr.com/
Partial Table of Contents:
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
UCB: PharmaVitae forecasts at a glance 8
Strategic insight 9
Epilepsy launches central to overcoming Keppra generics 9
Vimpat and Rikelta in line to replace Keppra as UCB's next-generation AED medications 9
Biopharmaceutical business model yet to deliver growth 11
SWOT analysis 12
Table of Contents 13
Table of figures 15
Chapter 3 Quarterly news update 16
Product developments 16
Deals and alliances 18
Product deals 18
Company announcements 19
Chapter 4 Company introduction 20
Key findings 20
Background 21
Key corporate developments 21
M&A history 22
Celltech 22
Schwarz Pharma 23
Chapter 5 Company sales 24
Key findings 24
Prescription pharmaceutical sales and growth rate analysis, 2002-14 25
Product analysis 26
Product analysis, 2002-08 27
Product analysis, 2008-14 30
Therapy area analysis 33
Geographic analysis 35
Launch/core/
Explanation of launch/core/
Launch analysis, 2008-14 38
Core analysis, 2008-14 39
Expiry analysis, 2008-14 40
Generics analysis, 2008-14 41
Launch/core/
Molecule type analysis 43
Externalization analysis 45
Chapter 6 Company financials 47
Key findings 47
Reconciliation between PharmaVitae-
Operating costs and profit analysis 49
Operating costs and profit analysis, 2002-08 50
Operating cost ratio and profit margin analysis, 2002-08 51
Operating cost ratio and profit margin analysis, 2008-14 52
Operating costs and profit analysis, 2008-14 53
Chapter 7 Key products and competitors 54
Key findings 54
Overview 55
Central nervous system 56
Keppra/Keppra XR 56
Overview 57
Sales forecast 58
Gold standard anti-epileptic drug 58
Launch of Keppra XR in September 2008 represents a clear lifecycle management strategy 59
Generics will erode a significant portion of the Keppra franchise's market share 60
Japan market penetration offers franchise some growth opportunity 60
Rikelta 61
Overview 62
Sales forecast 63
Next-generation version of Keppra currently in phase III trials 63
Datamonitor expects brivaracetam's target population to be treatment-refractory epilepsy patients 64
Neupro 65
Overview 66
Sales forecast 67
Novel Parkinson's formulation 67
Product recall in the US expected to slow uptake 67
Improved compliance and symptom control set to drive uptake 68
Vimpat 70
Overview 71
Sales forecast 72
Vimpat is the newest member of UCB's antiepileptic franchise 72
Approval as an adjunctive epilepsy treatment set to boost UCB offering 73
Neuropathic pain use rejected by FDA 73
Cannibalization of sales by brivaracetam represents a key threat to Vimpat 74
Immunology & inflammation 75
Cimzia 75
Overview 76
Sales forecast 77
UCB's novel anti-TNF mAb finally gets green light 77
Non-responder patient population and pricing offer key route to uptake 78
Cimzia is back in Phase III for Crohn's disease in the EU - Datamonitor updated its forecast to reflect impact of a Cimzia launch 78
Chapter 8 Appendix 80
Full ToC is available at:
-- http://www.fastmr.com/
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
